Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1341-1350

  Lin, Yung Chang ^a,b   Mahalingam, Jayashri ^a,b   Chiang, Jy Ming ^a,b   Su, Po Jung ^a   Chu, Yu Yi ^a   Lai, Hsin Yi ^a   Fang, Jian He ^a   Huang, Ching Tai ^a,b   Chiu, Cheng Tang ^a,b   Lin, Chun Yen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

colorectal cancer; effector memory T cells; regulatory T cell; tumor infiltrating lymphocyte

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; L SELECTIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COCARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DENSITY GRADIENT CENTRIFUGATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALE; MEMORY CELL; METASTASIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; COLORECTAL NEOPLASMS; CTLA-4 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84872932778     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27784     Document Type: Article

References (50)

1. Sakaguchi S,. Naturally arising Foxp3-expressing CD25 CD4 regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52. (Pubitemid 41716771)
2. Fontenot J, Rasmussen J, Williams L, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-41. (Pubitemid 40387475)
3. Zou W,. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
4. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8. (Pubitemid 40462939)
5. Nadkarni S, Mauri C, Ehrenstein M,. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007; 204: 33.
6. Curiel T,. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-74. (Pubitemid 46718401)
7. reg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 2006; 16: 124-36. (Pubitemid 43172061)
8. Qin F,. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol Immunol 2009; 6: 3-13.
9. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-72. (Pubitemid 32691889)
10. Okita R, Saeki T, Takashima S, et al. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005; 14: 1269-73.
11. Ling KL, Pratap SE, Bates GJ, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007; 7: 7.
12. Giannopoulos K, Schmitt M, Własiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222.
13. Cambien B, Karimdjee B, Richard-Fiardo P, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 2009; 100: 1755-64.
14. Clark R, Huang S, Murphy G, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205: 2221.
15. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007; 13: 2075-81. (Pubitemid 46649875)
16. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells. J Exp Med 2005; 202: 885.
17. Hong H, Gu Y, Zhang H, et al. Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin Exp Immunol 2010; 159: 93-9.
18. Clarke SL, Betts GJ, Plant A, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006; 1: e129.
19. Betts G, Jones E, Junaid S, et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2011.
20. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19: 345-54. (Pubitemid 46523383)
21. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: 1000-7.
22. Lehmann J, Huehn J, de la Rosa M, et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci USA 2002; 99: 13031-6.
23. Huehn J, Siegmund K, Lehmann JC, et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004; 199: 303-13. (Pubitemid 38252043)
24. Stephens GL, Andersson J, Shevach EM,. Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J Immunol 2007; 178: 6901-11. (Pubitemid 46847416)
25. Sather BD, Treuting P, Perdue N, et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007; 204: 1335-47. (Pubitemid 46919872)
26. Annacker O, Coombes J, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005; 202: 1051.
27. Zhao D, Zhang C, Yi T, et al. In vivo-Activated CD103+ CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008; 112: 2129.
28. Lin YC, Chang LY, Huang CT, et al. Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J Immunol 2009; 182: 6095-104.
29. Anz D, Mueller W, Golic M, et al. CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int J Cancer 2011; 129: 2417-26.
30. Wysocki C, Jiang Q, Panoskaltsis-Mortari A, et al. Critical role for CCR5 in the function of donor CD4+ CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 3300.
31. Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005; 105: 2877-86. (Pubitemid 40446282)
32. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
33. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
34. Chen X, Oppenheim JJ,. The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells. Immunology 2011; 133: 426-33.
35. Rudd CE, Taylor A, Schneider H,. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229: 12-26.
36. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-Associated antigen 4. J Exp Med 2000; 192: 303-10.
37. Mellman I, Coukos G, Dranoff G,. Cancer immunotherapy comes of age. Nature 2011; 480: 480-9.
38. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9. (Pubitemid 39273735)
39. Shen LS, Wang J, Shen DF, et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009; 131: 109-18.
40. Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009; 35: 569-81.
41. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-92.
42. Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33: 435-41.
43. Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012; 75: 95-101.
44. French JD, Weber ZJ, Fretwell DL, et al. Tumor-Associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2325-33.
45. Sinicrope FA, Rego RL, Ansell SM, et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-9.
46. Chen GY, Chen C, Wang L, et al. Cutting edge: broad expression of the FoxP3 locus in epithelial cells: A caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol 2008; 180: 5163-6.
47. Attig S, Hennenlotter J, Pawelec G, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69: 8412-9.
48. Chen X, Oppenheim JJ,. Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol 2011; 11: 1489-96.
49. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271.
50. Kryczek I, Wu K, Zhao E, et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011; 186: 4388-95.